All In Biotech

Drug Trial Radar · NCT01685424

Etoricoxib Prescribing Patterns and Adverse Events of Interest in Primary Care in the United Kingdom (MK-0663-162 AM1)

Etoricoxib Prescribing Patterns and Adverse Events of Interest During Etoricoxib Treatment in UK Primary Care; an Updated Analysis

Last checked: Nov 19, 2026Latest source record: Feb 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

79,189

Actual

Start

Jun 30, 2006

Primary completion

Mar 1, 2015

Study completion Mar 1, 2015

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Sep 14, 2012

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This postmarketing study was conducted to describe prescribing patterns for etoricoxib (ARCOXIA®) in General Practice and describe the incidence of selected adverse events recorded in the United Kingdom (UK) Medicines and Health Care Products Regulatory Agency (MHRA) General Practice Research Database (GPRD).

Conditions

  • Osteoarthritis
  • Rheumatoid Arthritis
  • Ankylosing Spondylitis
  • Gout
  • Arthritis

Interventions

  • EtoricoxibDrug

    As per routine clinical practice in the United Kingdom

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose of Initial Etoricoxib PrescriptionTime frame: At first prescription (during a time period up to 13.75 years)
  2. Duration of Initial Etoricoxib PrescriptionTime frame: At first prescription (during a time period up to 13.75 years)
  3. Participant's Baseline Characteristics (Demographics and Medical)Time frame: At first prescription (during a time period up to 13.75 years)
  4. Incidence of Adverse Events of Special Interest Among Etoricoxib UsersTime frame: During a time period up to 13.75 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.